Source: China Economic Network
Shipu Testing Technology (Shanghai) Co., Ltd
Sponsor (lead underwriter): Haitong Securities Co., Ltd
Release Status:
Company Profile:
Shipu Testing is a third-party testing organization specializing in soil and groundwater, covering soil, water quality, gas, solid waste, agricultural food and dioxins, covering environmental and food safety-related testing businesses from farmland to table.
The controlling shareholder of Shipu Testing is Real Spectrum Investment, which holds 52,003,300 shares of the company, with a shareholding ratio of 57.78%. The actual controllers of the company are Yang Jin and Wu Yaohua. Yang Jin directly holds 66.00% of the equity of Real Spectrum Investment, Wu Yaohua directly holds 20.00% of the equity of Solid Spectrum Investment, and the two indirectly hold 49.69% of the equity of Real Spectrum Investment. In addition, Yang Jin directly holds 87.43% of the equity of Shanghai Yishi and indirectly holds 4.33% of the equity of Shipu Detection through Shanghai Yishi; Wu Yaohua directly holds 68.96% of the equity of Shanghai Weili, and indirectly holds 6.64% of the equity of Shipu Detection through Shanghai Weili. In summary, Yang Jin and Wu Yaohua indirectly held 60.67% of the equity of Shipu Detection through Real Spectrum Investment, Shanghai Yishi and Shanghai Weili, forming a common control over the company.
After deducting the issuance fee, the funds raised by Shipu Testing will be used for the new laboratory project on Zhongchun Road, the construction project of the R&D information center, and the supplementary working capital.
Wuhan Huakang Century Medical Co., Ltd
Sponsor (lead underwriter): Huaying Securities Co., Ltd
Company Profile:
Huakang Medical Is a modern medical purification system integrated service provider, committed to solving the problem of medical infections, providing a clean, safe and intelligent medical environment for all kinds of hospitals, the main business includes medical purification system research and development, design, implementation and operation and maintenance, related medical equipment and medical consumables sales.
Tan Pingtao directly holds 46.709 million shares of Huakang Medical, accounting for 58.98% of the total number of shares of Huakang Medical, and is the controlling shareholder of Huakang Medical; Hu Xiaoyan, the spouse of Tan Pingtao, directly holds 3.1237 million shares of Huakang Medical, accounting for 3.94% of the total number of shares of Huakang Medical; at the same time, Tan Pingtao holds 48.93% of the property share of the employee shareholding platform Kanghui Investment, Hu Xiaoyan holds 0.49% of the property share of Kanghui Investment and serves as the executive partner of Kanghui Investment. Hu Xiaoyan indirectly controlled 4.8154 million shares of Huakang Medical through Kanghui Investment, accounting for 6.08% of the total share capital of the issuer. In summary, Tan Pingtao and his spouse control the total number of shares of Huakang Medical in total of 54.6481 million shares, accounting for 69.00% of the total shares of Huakang Medical, and Tan Pingtao and Hu Xiaoyan are the actual controllers of Huakang Medical.
After deducting the relevant issuance expenses, huakang medical funds raised in this stock offering will be invested in the following projects in accordance with the order of priority: technology research and development center upgrade project, marketing and operation and maintenance center construction project, and supplementary working capital.